Literature DB >> 27777147

Hypofractionation for Prostate Cancer: Time to Change.

D Dearnaley1, I Syndikus2, S Gulliford3, E Hall3.   

Abstract

Entities:  

Year:  2016        PMID： 27777147     DOI： 10.1016/j.clon.2016.09.020

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  5 in total

1.  The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study.

Authors:  Yaichiro Hashimoto; Atsushi Motegi; Tetsuo Akimoto; Norio Mitsuhashi; Junpei Iizuka; Kazunari Tanabe; Yuka Ishii; Sawa Kono; Sachiko Izumi; Kumiko Karasawa
Journal:  Int J Clin Oncol       Date:  2017-07-31       Impact factor: 3.402

2.  Hypofractionation trials and radiobiology of prostate cancer.

Authors:  Sarah Gulliford; Emma Hall; David Dearnaley
Journal:  Oncoscience       Date:  2017-04-14

3.  Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results.

Authors:  David Dearnaley; Emma Hall
Journal:  Transl Androl Urol       Date:  2017-02

Review 4.  MR-guided radiotherapy for prostate cancer: state of the art and future perspectives.

Authors:  Kobika Sritharan; Alison Tree
Journal:  Br J Radiol       Date:  2022-02-09       Impact factor: 3.039

5.  A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer.

Authors:  Kiyonao Nakamura; Itaru Ikeda; Haruo Inokuchi; Kenji Takayama; Takahiro Inoue; Tomomi Kamba; Osamu Ogawa; Masahiro Hiraoka; Takashi Mizowaki
Journal:  J Radiat Res       Date:  2018-09-01       Impact factor: 2.724
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.